However systemic therapy for lung cancer has been revolutionized for the subsets of patients with an EGFR mutation, ALK rearrangement or PD-L1 positivity by targeted agents which are initiated in appropriate clinical scenarios and based on widely available predictive biomarkers (9). The gene discussed is ALK; the disease is lung cancer.